Roche’s push into the obesity market has received another boost after its experimental drug, enicepatide, helped overweight or obese patients with type 2 diabetes improve blood sugar control while losing an average of 15.5% of their body weight in a mid-stage trial. The results add another potentially important asset to Roche’s efforts to challenge obesity-market leaders Eli Lilly and Company (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). Competition is also growing beyond the two incumbents, with companies including AstraZeneca PLC (NYSE:AZN) and Amgen Inc. (NASDAQ:AMGN) racing to develop new treatments.
DON’T MISS: Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
For Roche, the opportunity is substantial because the company is betting on next-generation therapies in an obesity market expected to exceed $100 billion in annual sales within the next decade. Enicepatide still has significant clinical development ahead, but its latest results give investors another indication of how Roche plans to compete for a piece of that market.
Bull Case
Enicepatide is a once-weekly injection designed to mimic the GLP-1 and GIP hormones, helping regulate blood sugar and reduce appetite. In the 447-patient mid-stage study, patients receiving the highest 24-milligram dose experienced significant reductions in HbA1c at 48 weeks, meeting the study’s two main goals. HbA1c measures blood-glucose levels over time. Roche said approximately 62% of patients achieved HbA1c levels below 5.7%, putting their blood sugar into the non-diabetic range.
Those findings follow another mid-stage result reported in June, when the company reported that in that study, enicepatide helped overweight or obese patients without diabetes lose 22.7% of their body weight. The two weight-loss figures should not be directly compared because they come from separate trials involving different patient populations. Taken individually, however, both provide clinical evidence supporting Roche’s decision to continue developing enicepatide.
DON’T MISS: Pfizer vs. Thermo Fisher: Which Healthcare Turnaround has More Upside?
The next step is already taking shape with Roche planning to begin late-stage glycemic-control and cardiovascular-outcomes studies during the first half of 2027. Advancing into late-stage development would move enicepatide closer to answering the larger question of whether Roche can establish a meaningful position in the increasingly competitive obesity market.
Bear Case
Despite the encouraging mid-stage results, enicepatide remains an experimental drug, and Roche still has substantial clinical work ahead before it could become a commercial competitor to established obesity treatments. The planned late-stage studies are not expected to begin until the first half of 2027, which means the latest results should not be treated as evidence of regulatory approval or eventual commercial success.
Tolerability will also remain an important part of the drug’s development. Roche said around 2% of patients taking enicepatide in the 447-patient study discontinued treatment because of side effects, compared with none in the placebo group. Most gastrointestinal side effects were described by the company as mild to moderate.
Competition presents another challenge for the company. Roche is not entering an undeveloped market, but rather one where Eli Lilly and Novo Nordisk are already the leaders, while AstraZeneca and Amgen are among the large drugmakers also racing to break into obesity treatments. The scale of the potential market therefore cuts both ways. Expectations that annual obesity-drug sales could eventually exceed $100 billion help explain Roche’s investment in next-generation therapies, but the size of the opportunity is also attracting significant competition.
Conclusion
Enicepatide gives Roche another credible clinical program around which to build its obesity ambitions. The latest study met its two main goals, with the highest dose producing significant improvements in HbA1c alongside average weight loss of 15.5%. That follows the separate June study showing 22.7% weight loss among overweight or obese patients without diabetes.
But Roche is still approaching the stage where the evidence will become more demanding. Enicepatide remains in mid-stage development, with late-stage glycemic-control and cardiovascular-outcomes studies planned for the first half of 2027. For now, the results strengthen Roche’s case for continuing to invest in enicepatide. Whether the drug can eventually challenge Eli Lilly and Company and Novo Nordisk A/S will depend on what Roche can demonstrate as the program moves into late-stage testing.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center